Presented on June 8, 2021

Patient-Derived Organoids & Assays for Cancer Research

With the increasing use of 3D cell structures for modeling tumors, organs, and tissue for translation research, there is a requirement for cancer models, assays and workflows to study patient-derived samples. In this webinar the speakers presented efforts of a successful collaboration of using our automated assay system (the Pu·MA System) with patient-derived organoids for developing an efficient workflow which was incorporated into a translational project which addressed therapeutics and drug resistance in triple negative breast cancer 


Margarite and Katya - Jun 2021

  • Margarite Matossian, MD PhD (Tulane University Medical University)
    Physician-Scientist in the group of Dr. Matthew Burow (Burow Lab website. 
    This study was funded by NIH & Krewe de Pink)
    Patient-Derived Organoids: Translational Oncology research to Interrogate Therapeutic Responses & Drug Resistance


  • Katya Nikolov, MD (Protein Fluidics, Inc.)
    Senior Application Scientist
    Automated Assays with Patient-Derived Organoids using the Pu·MA System

Learn how:

  • The Pu·MA System can help prevent loss or damage during assay steps such as media exchange, supernatant sampling, or immunofluorescence staining.  
  • Patient-derived organoids were cultured from breast cancer patient samples for studying drug resistance 
  • To use these methods in a simple unified workflow
For previous webinar recordings, check out our Webinars page

Contact Us

Protein Fluidics, Inc.

875 Cowan Road, Suite B,
Burlingame, CA 94010

+1 650 529 5080


Our Company

For Research Use Only. Not for diagnostic use. Protein Fluidics, Protein Fluidics Logo and Pu•MA System are registered trademarks of Protein Fluidics, Inc. in the United States and internationally. All rights reserved. © 2021 PROTEIN FLUIDICS, INC.